Somewhat Positive Press Coverage Somewhat Unlikely to Impact Neothetics (NEOT) Stock Price

Headlines about Neothetics (NASDAQ:NEOT) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neothetics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.5542308498384 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Separately, ValuEngine raised shares of Neothetics from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 17th.

Shares of Neothetics (NASDAQ NEOT) opened at $1.74 on Tuesday. Neothetics has a fifty-two week low of $0.30 and a fifty-two week high of $2.63. The stock has a market cap of $25.11, a P/E ratio of -2.52 and a beta of 3.30.

Neothetics (NASDAQ:NEOT) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at

Neothetics Company Profile

Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

Insider Buying and Selling by Quarter for Neothetics (NASDAQ:NEOT)

Receive News & Ratings for Neothetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit